Current status and challenges in HER2 IHC assessment: scoring survey results in Japan.

Autor: Sakatani T; Department of Diagnostic Pathology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo-Ku, Tokyo, 113-8603, Japan. takashi-sakatani@nms.ac.jp., Tsuda H; Department of Basic Pathology, National Defense Medical College, Saitama, Japan., Yoshida M; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan., Honma N; Department of Pathology, Faculty of Medicine, Toho University, Tokyo, Japan., Masuda S; Department of Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan., Osako T; Division of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan., Hayashi A; Medical Scientific Affairs, Healthcare Excellence, Roche Diagnostics K.K, Tokyo, Japan., Jara-Lazaro AR; Roche Diagnostics Asia Pacific, Singapore, Singapore., Horii R; Department of Pathology, Saitama Cancer Center, Saitama, Japan.; Department of Pathology, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.
Jazyk: angličtina
Zdroj: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Nov 04. Date of Electronic Publication: 2024 Nov 04.
DOI: 10.1007/s10549-024-07532-2
Abstrakt: Purpose: This study aimed to assess the concordance of human epidermal growth factor receptor 2 (HER2) expression scoring by immunohistochemistry (IHC) among practicing pathologists in Japan, given the challenging nature of scoring and the critical role of HER2 status in breast cancer management.
Methods: Whole slide images (WSI) from 20 invasive breast cancer cases (1 representative WSI per case) selected to represent a diverse IHC scores and staining patterns were used in an online survey involving seven reference pathologists who established consensus HER2 IHC scores (0 to 3 +) decided by majority interpretation. Participating pathologists nationwide scored the same 20 WSI cases online using the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2018 guidelines. Deidentified case metadata were registered in the uPath system.
Results: A total of 144 participating pathologists responded. The scoring results of the participating pathologists most commonly agreed with the consensus IHC score, followed by a ± 1 point deviation and no survey responses with > 1 point deviation. The mean percentage of agreement with the consensus score for all 20 cases was 63.4%. In cases where the reference pathologists' scores were discordant, the participating pathologists also showed a lower concordance rate.
Conclusion: This study highlighted the current status of HER2 expression scoring by IHC for breast cancer among pathologists in Japan. These findings underscore the challenges in HER2 IHC scoring cases and emphasize the need for improved standardization and training, especially in the evolving landscape of HER2-targeted therapies.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: